Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30476991 | 0.79 | NOS1 (0.45) | NOS1MAPTALDH1A1LPLLIPG | |
| SCHEMBL15796934 | 0.79 | NOS1 (0.45) | NOS1MAPTALDH1A1LPLLIPG | |
| SCHEMBL30005142 | 0.77 | NOS1 (0.39) | NOS1UCHL1 | |
| SCHEMBL21653719 | 0.77 | NOS1 (0.39) | NOS1UCHL1 | |
| SCHEMBL3496375 | 0.77 | NOS1 (0.36) | NOS1UCHL1 | |
| SCHEMBL29363742 | 0.75 | — | — | |
| SCHEMBL29468945 | 0.75 | MAPT (0.49) | NOS1MAPTALDH1A1HTTLPL | |
| SCHEMBL21379213 | 0.75 | MAPT (0.49) | NOS1MAPTALDH1A1HTTLPL | |
| SCHEMBL24616920 | 0.73 | UCHL1 (0.32) | UCHL1LPLLIPG | |
| SCHEMBL3496478 | 0.72 | MAPT (0.35) | MAPTHTTUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| EP-4302834-A2 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116478131-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116478132-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-11033547-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11033547-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| US-20200281926-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-09-10 | — | — | US | disclosed |
| US-20200281926-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-09-10 | — | — | US | disclosed |
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | NOS1 1290/4885MAPT 3793/4885DYRK1A 754/4885 |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | NOS1 3875/4885MAPT 3462/4885DYRK1A 578/4885 |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | PTPN5, PTPN2, PTPN1 | NOS1 3629/4885MAPT 4596/4885DYRK1A 658/4885 |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | NOS1 3875/4885MAPT 3462/4885DYRK1A 578/4885 |
| US-11033547-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | PTPN5, PTPN2, PTPN1 | NOS1 3629/4885MAPT 4596/4885DYRK1A 658/4885 |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN22, PTPN2 | NOS1 1290/4885MAPT 3793/4885DYRK1A 754/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | NOS1 3789/4885MAPT 2897/4885DYRK1A 757/4885 |
| US-20200281926-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | PTPN5, PTPN2, PTPN1 | NOS1 3629/4885MAPT 4596/4885DYRK1A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.